Enfusion Inc

Enfusion — Q3 2024 Earnings Presentation

26 slides from Enfusion's earnings presentation, Nov 4, 2024

  1. Slide 1: Enfusion 3Q 2024 Shareholder Letter

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Enfusion 3Q 2024 Shareholder Letter November 2024

  2. Slide 2: Disclaimer: Forward-Looking Statements

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Disclaimer 2 Forward-Looking Statements Statements we make in this presentation may include statements which are not historical facts and are considered forward-looking within the meaning of Section 27A of the Securities Act of 1933 (Securities Act) and Section 2

  3. Slide 3: Dear Shareholders

    ©2024 ENFUSION. ALL RIGHTS RESERVED. 3 Dear Shareholders, Enfusion had another solid quarter, generating revenue of $51.2M, translating to 15.4% year over year revenue growth combined with year over year expansion of adjusted EBITDA margins. We won 38 new accounts this quarter, bringing our total cl

  4. Slide 4: Our Mission

    ©2024 ENFUSION. ALL RIGHTS RESERVED. 4 Our Mission To power all investment workflows with our unparalleled technology, relentless innovation, and dedicated focus on clients All Workflows Durable Financial Profile Relentless Innovation World Class Team Enfusion’s Mission We deliver exceptional tech e

  5. Slide 5: Enfusion is a Unique Collaboration Platform

    ©2024 ENFUSION. ALL RIGHTS RESERVED. 4 ENFUSION. ALLRIGHTS RESERVED. Compliance Trading Risk Operations Investor Relations Business Development Portfolio Managers Research Enfusion is a Unique Collaboration Platform Our SaaS architecture & product roadmap expand collaboration for all related workflo

  6. Slide 6: Time to disrupt the traditional asset management segment: $25B TAM

    ©2024 ENFUSION. ALL RIGHTS RESERVED. 6 It is our time to disrupt the traditional asset management segment the same way we disrupted the alternatives segment Untapped Upside Potential: $25B TAM $25B $15.3B $1.2B $1.3B $7.2B Private Equity & Private Credit Firms Equity Hedge Funds Non-Equity Hedge Fun

  7. Slide 7: Evolution of the Enfusion Product: 2024

    ©2024 ENFUSION. ALL RIGHTS RESERVED. OEMS & Compliance Portfolio Management Solutions Portfolio Construction Workbench Decision Analytics Portfolio Analytics Reporting Reference Data Book of Record Managed Services Back-office Accounting and Operations Future roadmap Inception 2024 Evolution of the

  8. Slide 8: The Perfect Storm: Why Enfusion Wins

    ©2024 ENFUSION. ALL RIGHTS RESERVED. 8 The Perfect Storm: Why Enfusion Wins Built with multi-tenant SaaS architecture from day one Enfusion’s History Trailblazing technology foundational to future growth Client’s Race to Cloud & Scalability Client’s Time-to-Market Pressures Macro Market Trends Elect

  9. Slide 9: 3Q24 Key Financial Highlights

    ©2024 ENFUSION. ALL RIGHTS RESERVED. 3Q24 Key Financial Highlights Highly attractive SaaS model with combination of scale, growth and profitability $ in millions 9 (1) See appendix for definition and non-GAAP reconciliations. Adjusted Free Cash Flow FCF Conversion Z00 Total Revenue YoY Growth Z00 Ad

  10. Slide 10: Strong Growth

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Strong Growth $ in millions $44.4 $46.5 $48.1 $49.5 $51.2 3Q23 4Q23 1Q24 2Q24 3Q24 Revenue 10 (1) (1) (1) $(4.1) Gross Profit and Adjusted Gross Profit (1) (1) See appendix for non-GAAP reconciliations. $29.9 $30.9 $31.9 $33.5 $34.8 $30.2 $31.1 $32.6 $33.9 $35.2

  11. Slide 11: Improving Profitability

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Improving Profitability 67.3% 66.4% 66.3% 67.7% 68.0% 68.1% 66.9% 67.8% 68.5% 68.8% 3Q23 4Q23 1Q24 2Q24 3Q24 Gross Margin Adjusted Gross Margin Gross Margin and Adjusted Gross Margin (1) 11 (1) (1) (1) $(4.1) Net Income Margin and Adjusted EBITDA Margin (1) (1) S

  12. Slide 12: Improving Profitability

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Improving Profitability 12 (1) See appendix for non-GAAP reconciliations. (1) (1) $(4.1) $ in millions Net Income and Adjusted EBITDA(1) (1) Operating Cash Flow and Adjusted Free Cash Flow(1) $2.7 $0.9 -$0.8 $2.5 $2.0 $8.2 $9.8 $9.2 $10.1 $11.1 3Q23 4Q23 1Q24 2Q2

  13. Slide 13: Organic client growth and expansion continues to scale

    ©2024 ENFUSION. ALL RIGHTS RESERVED. $177.9 $185.1 $190.5 $195.7 $202.7 3Q23 4Q23 1Q24 2Q24 3Q24 102.4% 102.1% 102.9% 103.0% 102.1% 3Q23 4Q23 1Q24 2Q24 3Q24 Organic client growth and expansion continues to scale 13 842 865 868 879 894 3Q23 4Q23 1Q24 2Q24 3Q24 $217 $219 $226 $228 $229 3Q23 4Q23 1Q24

  14. Slide 14: Front Book + Back Book = Total Revenue Growth

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Front Book + Back Book = Total Revenue Growth 14 Front Book = Onboarding Of New Logos Back Book = Growth From Our Existing Customer Base Front Book = Onboarding Of New Logos 16.4% 13.4% 14.2% 14.8% 14.6% -3.1% 1.3% 3.1% 1.0% 0.8% 13.3% 14.7% 17.3% 15.8% 15.4% 3Q2

  15. Slide 15: Client ARR Distribution and ACV

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Client ARR Distribution and ACV Client Book continues to evolve toward larger ACV clients 15 65% 56% 47% 44% 43% 19% 24% 30% 30% 30% 16% 20% 23% 26% 27% $156 $182 $201 $217 $229 ϯYϮϬ ϯYϮϭ ϯYϮϮ ϯYϮϯ ϯYϮϰ Evolution of Customer Size Segments - ARR Distribution Less

  16. Slide 16: 2024 Updated Guidance

    ©2024 ENFUSION. ALL RIGHTS RESERVED. 2024 Updated Guidance 16 FCF Conversion is adjusted Free Cash Flow divided by Adjusted EBITDA. Adjusted EBITDA guidance excludes stock-based compensation of $19-20 million for the full year of 2024, of which we estimate approximately 1/3 occurred in 1Q24. These s

  17. Slide 17: Medium Term Guidance (2025 - 2027)

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Medium Term Guidance (2025 - 2027) 17 Financial Metrics No Change Annual Revenue Growth 20-22% Annual Adjusted EBITDA Margin Expansion 200-400 bps Annual FCF Conversion Expansion 300-500 bps These statements are forward-looking and actual results may differ mater

  18. Slide 18: Appendix

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Appendix

  19. Slide 19: Consolidated Balance Sheets

    ©2024 ENFUSION. ALL RIGHTS RESERVED. ENFUSION, INC. CONSOLIDATED BALANCE SHEETS (dollars and shares in thousands, except par value) 19 ASSETS Current assets: Cash and cash equivalents $ 48,299 $ 35,604 Accounts receivable, net 28,069 32,173 Prepaid expenses 5,009 3,576 Other current assets 1,170 1,3

  20. Slide 20: Consolidated Statements of Operations

    ©2024 ENFUSION. ALL RIGHTS RESERVED. ENFUSION, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (dollars and shares in thousands, except per share amounts) (Unaudited) 20 REVENUES: Platform subscriptions $ 47,786 $ 40,857 Managed services 3,078 3,028 Other 472 302 Total revenues 51,166 44,357 COST OF REVE

  21. Slide 21: Consolidated Statements of Cash Flows

    ©2024 ENFUSION. ALL RIGHTS RESERVED. ENFUSION, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (dollars and shares in thousands, except per share amounts) (Unaudited) 21 Cash flows from operating activities: Net income $ $ 8,353 3,743 Adjustments to reconcile net income to net cash provided by operating

  22. Slide 22: Reconciliations To Non-GAAP Financial Measures

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures The following table reconciles net income to adjusted EBITDA: The following table reconciles gross profit to adjusted gross profit: 22 ($ in thousands, unaudited) September 30, 2023 December 31, 2023 March 31, 2024 J

  23. Slide 23: Reconciliations To Non-GAAP Financial Measures

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures The following table reconciles operating cash flow to adjusted free cash flow: The Company’s stock-based compensation expense was recognized in the following captions within the consolidated statements of operations:

  24. Slide 24: Reconciliations To Non-GAAP Financial Measures

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Reconciliations To Non-GAAP Financial Measures The following table reconciles net income to adjusted net Income which is used to calculate adjusted diluted EPS: 24 (unaudited) Per share Per share Net income and fully diluted EPS $ 0.02 1,957 $ 0.02 2,661 Adjustme

  25. Slide 25: Definitions

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Definitions OCF Margin Operating Cash Flow Margin represents net cash provided from operating activities divided by total net revenues. We believe OCF Margin is an important metric because it indicates our ability to convert sales into cash. Non-GAAP Financial Me

  26. Slide 26: Definitions Continued

    ©2024 ENFUSION. ALL RIGHTS RESERVED. Definitions Continued Adjusted Net Income and Adjusted Diluted EPS Adjusted Net Income represents net income adjusted to exclude stock-based compensation expense, the effect of foreign currency fluctuations, certain non-recurring items, and the tax effect of such

Enfusion — Q3 2024 Earnings Presentation on 6ix